logo
Bond Investors Sound The Alarm

Bond Investors Sound The Alarm

Forbes2 days ago

CHICAGO, IL - MARCH 15: Traders watch prices in the Ten-Year Treasury Note options pit at the CME ... More Group following the announcement by the Federal Open Market Committee (FOMC) that they would maintain the key policy rate near zero on March 15, 2011 in Chicago, Illinois. U.S. stock and commodity prices tumbled today following a sharp drop in Japan’s stock market, as investors worldwide worry about the economic impact of that country's recent earthquake, tsunami and unfolding nuclear crisis. (Photo by)
The financial markets in 2025 have been a whirlwind of volatility, with the stock market battered by economic policy shocks and the bond market grappling with its own turbulence. The 10-year Treasury yield, a critical barometer of economic health, has oscillated between approximately 4.0% and 4.47% this year, injecting unprecedented volatility into a market typically known for its stability.
For bond investors, the chaos stems from a volatile mix of aggressive policy moves, resurgent inflation fears, and a looming fiscal crisis—culminating in the House passage of the controversial One Big Beautiful Bill Act. As the Senate debates this transformative legislation, bond investors are bracing for higher yields and the economic fallout that could follow.
Treasury Secretary's Ambitious But Elusive Goal
From the moment Scott Bessent, sworn in as Treasury Secretary on January 28, 2025, took office, he declared lowering interest rates—particularly the 10-year Treasury yield—his top priority. With roughly half of the U.S.'s $1.9 trillion annual deficit tied to interest payments of $952 billion, according to the Congressional Budget Office, reducing yields is critical to slowing the growth of the national debt.
Early in 2025, bond markets gave Bessent the benefit of the doubt and yields briefly dipped as investors anticipated progress. However, optimism has since given way to skepticism, as a series of policy missteps and economic headwinds have made Bessent's goal seem increasingly unattainable.
Bond investors, known for their forward-looking analysis, are now pricing in a future of higher yields, driven by inflationary pressures and ballooning deficits. The disconnect between Bessent's stated objectives and the administration's policy actions has left the bond market on edge, with significant implications for the broader economy.
Tariffs Spark Inflation Fears
The bond market's unease began in earnest on April 2, 2025—dubbed 'Liberation Day' by President Trump—when the administration unveiled sweeping tariffs on nearly all imported goods. The announcement blindsided markets, triggering a sharp repricing of risk. The stock market embarked on a weeks-long slide, while the 10-year Treasury yield surged from around 4.0% to nearly 4.5% in just three days—an extraordinary move for the typically sedate Treasury market.
For bond investors, the tariffs signaled a clear and present danger: resurgent inflation. Higher costs for imported goods could ripple through the economy, driving up consumer prices and forcing the Federal Reserve to maintain elevated interest rates. This directly undermines Bessent's goal of lowering yields, as bond investors demand higher returns to offset the risk of rising inflation. The tariffs have also strained global trade relationships, further clouding the economic outlook and adding to market uncertainty.
A Credit Downgrade Deepens Concerns
On May 16, 2025, Moody's delivered another blow, downgrading the U.S. credit rating from AAA to Aa1, the last major credit rating agency to take this step. Citing ballooning deficits, a growing national debt, and rising borrowing costs, the downgrade confirmed what many bond investors had already feared. While the move was not entirely unexpected, markets are still processing its implications, particularly as they await clarity on Republican budget legislation.
The downgrade underscores the precarious state of U.S. fiscal health. With deficits projected to widen, bond investors are increasingly wary of holding U.S. debt without higher yields to compensate for the added risk. This dynamic further complicates Bessent's mission to lower interest rates, as rising borrowing costs threaten to spiral out of control.
The One Big Beautiful Bill Act: A Fiscal Reckoning
The passage of the One Big Beautiful Bill Act by the House of Representatives on May 22, 2025, by a 215-214 vote, has only intensified these concerns. Far from the fiscal restraint one might expect from a Republican-led initiative, the bill is projected to add $5.1 trillion to the national debt over the next decade if extended, according to the Committee for a Responsible Federal Budget. Now under consideration in the Senate, where significant changes are expected, the legislation signals a trajectory of growing deficits—a red flag for bond investors.
The bill's fiscal hubris directly undermines Bessent's goal of reducing borrowing costs. Higher deficits mean increased Treasury issuance, which could flood the bond market and drive yields higher as investors demand greater compensation. With inflation concerns already heightened by tariffs, the Federal Reserve has little room to cut rates, leaving bond yields—and borrowing costs—poised to rise further. This creates a vicious cycle: higher yields increase the cost of servicing the national debt, further widening deficits and necessitating even more borrowing.
The Broader Economic Fallout
The implications of rising Treasury yields extend far beyond the bond market. Higher yields increase borrowing costs for businesses and consumers, slowing economic growth and putting pressure on everything from corporate expansions to mortgage rates. While the stock market's volatility grabs headlines, the bond market's dynamics have a more direct and profound impact on economic activity. As yields rise, borrowers—both corporate and individual—find themselves in a precarious position, with ripple effects that could dampen investment and consumer spending.
For investors, the message is clear: the bond market is sounding a warning. The combination of tariff-driven inflation, a credit downgrade, and the One Big Beautiful Bill Act's fiscal blind spots creates a perfect storm for higher yields. This could weigh heavily on stock portfolios, as slower growth and tighter financial conditions erode corporate profits and investor confidence.
As the Senate debates the One Big Beautiful Bill Act, bond investors are watching closely. Any indication that the final legislation will further inflate deficits could push yields higher still, threatening economic stability and undermining Bessent's goal of lower interest rates. For now, the bond market is sending a clear signal: bold policy promises are no match for fiscal realities. Investors would be wise to monitor Treasury yields closely and consider the risks posed to their portfolios in the year ahead. In a market defined by uncertainty, the bond market's message is unmistakable: brace for impact.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Does Medicare Cover Trulicity?
Does Medicare Cover Trulicity?

Health Line

time13 minutes ago

  • Health Line

Does Medicare Cover Trulicity?

Medicare Part D plans and some Part C plans may cover Trulicity (dulaglutide) for diabetes, but the exact coverage depends on the plan. Such plans will only cover this drug for weight loss in certain cases if you're living with obesity. Trulicity (dulaglutide) is a drug belonging to the glucagon-like peptide-1 receptor agonist (GLP-1) class of medications. Diabetes affects 38.4 million people in the United States, or 11.6% of the population. The Food and Drug Administration (FDA) has approved this drug to help manage type 2 diabetes and reduce the chance of developing heart disease. For this reason, although GLP-1s may be prescribed off-label for weight loss, Medicare Part D plans may cover this drug for diabetes management but not for weight loss, except under specific circumstances. Is Trulicity covered by Medicare Part B? Medicare is generally divided into the following parts: Original Medicare (parts A and B) Medicare Part D Medicare Part C (Medicare Advantage) Medigap Part B Part B mainly covers medications that you cannot administer yourself, such as IV infusions, for example. While Trulicity is an injection drug, it is one that you can inject yourself. For this reason, Medicare Part D would be responsible for covering a drug like Trulicity. Part D Since private insurers manage Part D plans, the exact drugs that each plan covers vary. What drugs a specific plan covers depends on its formulary, which is a list of the covered drugs. Part D plans are generally required to cover at least two drugs from the most commonly prescribed categories. If the plan does not cover Trulicity (dulaglutide), it is likely to cover some brand-name or generic alternative. Medicare's plan finder tool allows you to enter medications you take to see which Part D plans in your area include these medications in their formulary. The tool also lets you compare prices at different pharmacies in your area. Part C Medicare Part C, also called Medicare Advantage, is another option for healthcare coverage under Medicare. These optional, private plans offer the same benefits as Original Medicare. Some Part C plans may also offer other benefits, such as prescription drug coverage. Coverage for specific medications under a Medicare Advantage plan depends on the options and plans that the company you choose offers. When selecting a Medicare Advantage plan, you can specify medications you take to compare coverage and pricing. Why doesn't Medicare cover Trulicity for weight loss? Medicare drug plans typically cover medications when they are considered medically necessary. Therefore, Part D plans or Part C plans with drug coverage won't cover GLP-1 agonists like Trulicity for weight loss. Typically, coverage focuses on FDA-approved uses such as helping manage type 2 diabetes or lowering cardiovascular risks for overweight adults or those living with obesity. Obesity is defined as having a body mass index (BMI) of 30 or greater. This means you could have a BMI between 25 and 30, but would not qualify for a drug like Trulicity through Medicare unless you need it for diabetes. Under the Biden administration, the Centers for Medicare & Medicaid Services (CMS) looked into expanding coverage of GLP-1 drugs for weight loss by 2026. However, the Trump administration has since decided against this expansion. How much does Trulicity cost on Medicare? Trulicity's list price is $987.19 per month, but insurance or Medicare coverage may lower this cost. When a Medicare drug plan covers a drug, how much you'll pay out of pocket depends on the tier your plan classifies the drug within its formulary. Generally, higher-tier drugs cost more. Copays for this medication will vary based on the plan you choose, but the manufacturer suggests a range of $0 to $100 per month after you've met your Medicare Part D deductible. Generic drugs are generally classified in a lower tier, but no generic Trulicity is currently available. How can I lower the cost of Trulicity? Trulicity's manufacturer offers a savings card through which you can get a one-month supply of Trulicity for as little as $25. However, you won't be able to use your Medicare plan if you want this discount. Alternatively, you can check whether you qualify for Extra Help, which can lower your prescription costs to $4 to $9. Other resources for lowering drug costs include: Other tips that may help lower your prescription drug costs include: Ask your doctor about less expensive generic options. Consider switching from a 30-day supply to a 90-day supply for your medications, as buying a larger supply upfront can provide cost savings. Consider a mail-order supplier to save on costs. What is a cheaper alternative to Trulicity? The following chart shows GLP-1 agonists currently available in the United States and their brand-name retail prices before insurance. Available generic versions usually cost less. Brand name (generic name) List price as of 2025 Wegovy (semaglutide) $1,349.02 Ozempic (semaglutide) $997.58 Rybelsus (semaglutide $997.58 Mounjaro (tirzepatide) $1,079.77 Zepbound (tirzepatide) $1,086.37 Saxenda (liraglutide) $1,349.02 Victoza (liraglutide) $543.51 or $815.27 (depending on dose) Trulicity (dulaglutide) $987.19 In addition, other diabetes medications can be covered by Medicare. CMS included several of these drugs in the list of 10 drugs it used to renegotiate prices as part of the Inflation Reduction Act of 2022. Takeaway Trulicity is a long-lasting brand-name medication that can be quite effective at lowering high blood sugar levels due to type 2 diabetes. It is not a substitute for insulin or diet and lifestyle strategies for managing diabetes. There is no generic version of this medication. It is typically a tier 3 medication in most drug plan formulary lists. Many Medicare Part D plans include Trulicity on formularies, but you'll likely still pay a share of the costs. The cost you'll pay will depend on your specific plan. A variety of private and public programs offer extra help in covering your medication costs. You can also talk with your doctor about an affordable way to manage diabetes. The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.

After Boulder attack, Los Angeles mayor calls emergency meeting to discuss police patrols at houses of worship
After Boulder attack, Los Angeles mayor calls emergency meeting to discuss police patrols at houses of worship

CBS News

time14 minutes ago

  • CBS News

After Boulder attack, Los Angeles mayor calls emergency meeting to discuss police patrols at houses of worship

Los Angeles Mayor Karen Bass on Sunday night called for an emergency meeting to discuss law enforcement strategies during the fallout of what the FBI called a "targeted act of violence" in Colorado over the weekend. In a statement posted to X, Bass called for extra police patrols at places of worship and community centers across L.A. "Anti-Semitism will not be tolerated in this city," she said. On Sunday, a man is accused of using a "makeshift flamethrower" and Molotov cocktails to attack a peaceful march in support of Israeli hostages at the Pearl Street Mall in Boulder, a popular outdoor pedestrian area lined with shops and restaurants. The aftermath of an alleged act of terror that left eight people injured during a march in support of Israeli hostages in Boulder, Colorado on Sunday, June 1, 2025. CBS The Boulder Police Department said eight people were injured in the attack. The FBI identified the suspect as 45-year-old Mohamed Sabry Soliman, who allegedly yelled "Free Palestine" as he conducted the attack. CBS Colorado reported Sunday that Soliman is an Egyptian national and could be living in the U.S. on an expired visa. At least one person was in serious condition as of Sunday night, per authorities. The age range of the victims was 52 to 88, police said. The 88-year-old victim is a Holocaust refugee who fled Europe, CBS Colorado reports. The attack came on the first evening of the Jewish holiday Shavuot, which runs until Tuesday. Bass on Sunday night said the emergency meeting at L.A. City Hall will take place immediately after the holiday. The mayor also stated that the LAPD would conduct extra patrols in areas such as "houses of worship and community centers" in light of the attack. "What happened in Boulder, Colorado today — an especially brutal targeting of elders — is an atrocious affront to the very fabric of our society and our beliefs here in Los Angeles," she said.

How To Watch CNN's Special Presentation of George Clooney's 'Good Night, and Good Luck' on Saturday, June 7 at 7pm ET
How To Watch CNN's Special Presentation of George Clooney's 'Good Night, and Good Luck' on Saturday, June 7 at 7pm ET

CNN

time18 minutes ago

  • CNN

How To Watch CNN's Special Presentation of George Clooney's 'Good Night, and Good Luck' on Saturday, June 7 at 7pm ET

June 2nd, 2025 NEW YORK – (JUNE 2, 2025) – CNN will broadcast live the penultimate performance of Good Night, and Good Luck from Broadway's Winter Garden Theatre on Saturday, June 7 at 7pm ET across CNN and CNN International and will stream the event live on and via CNN's apps on connected TVs and mobile devices, without requiring a cable login. This CNN special event will stream live on Max across all subscription plans. This special CNN presentation of the five-time Tony® Award nominated new play by George Clooney and Grant Heslov marks a historic Broadway first: never before has a live play ever been broadcast and televised. CNN anchors Anderson Cooper and Pamela Brown will lead special live coverage. CNN will bring this timely production to audiences around the world, beginning with special live coverage at 6:30pm ET hosted by Brown outside of the Winter Garden Theatre. At 7pm ET, Good Night, and Good Luck will air live on CNN and CNN International and stream live without requiring a cable login via and on connected TVs and mobile apps. It will also stream live on Max across all subscription plans. Immediately following the broadcast, CNN will host an exclusive special to discuss the critically acclaimed production and state of global journalism hosted by Cooper. In this landmark theatrical and live television event, two-time Academy Award® winner and Tony Award® nominated George Clooney makes his Broadway debut as Edward R. Murrow, showcasing his legendary, history-altering, on-air showdown with Senator Joseph McCarthy. As McCarthyism casts a shadow over America, Murrow and his news team choose to confront the growing tide of paranoia and propaganda, even if it means turning the federal government and a worried nation against them. Good Night, and Good Luck recently made history by becoming the highest-grossing play in Broadway history, and the first play to surpass a gross of $4 million in a single week. Nominated for five Tony Awards, Good Night, and Good Luck, co-written by Clooney and Heslov, is directed by Tony Award winner David Cromer. Producers are Seaview, Sue Wagner, John Johnson, Jean Doumanian and Robert Fox. Based on the 2929 Entertainment and Participant film of the same name distributed by Warner Bros. and written by the same authors, the following actors portray real life figures alongside Mr. Clooney as Murrow: Mac Brandt as Colonel Anderson, Will Dagger as Don Hewitt, Christopher Denham as John Aaron, Glenn Fleshler as Fred Friendly, Ilana Glazer as Shirley Wershba, Clark Gregg as Don Hollenbeck, Paul Gross as William S. Paley, Georgia Heers as Ella, Carter Hudson as Joe Wershba, Fran Kranz as Palmer Williams, Jennifer Morris as Millie Green, Michael Nathanson as Eddie Scott, Andrew Polk as Charlie Mack, Aaron Roman Weiner as Don Surine with R. Ward Duffy, Joe Forbrich, Imani Rousselle, Greg Stuhr, JD Taylor, and Sophia Tzougros rounding out the ensemble. The creative team for Good Night, and Good Luck includes Tony Award winner Scott Pask (scenic design), Heather Gilbert (lighting design), David Bengali (video/projections design), Daniel Kluger (sound design), Brenda Abbandandolo (costume design), Leah J. Loukas (hair & wig design), Gigi Buffington (voice & dialect), Daniel Kluger and Bryan Carter (music supervision), and David Caparelliotis (Casting Director). Good Night, and Good Luck is produced by Seaview, Sue Wagner, John Johnson, Jean Doumanian and Robert Fox. PRESS CONTACT ASSETS To download production photos, click here. An additional portrait featuring the entire cast on stage can be downloaded here. ###

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store